Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06242860 · ClinicalTrials.gov registry record · NA
Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease
A NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, sponsored by Eyedetec Medical.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT06242860: Completed NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, sponsored by Eyedetec Medical.
NCT06242860 is a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease that has completed, run by Eyedetec Medical. The registered enrollment target is 31 participants, below the 99-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06242860, a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, has completed, sponsored by Eyedetec Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the Eye Lipid Mobilizer (ELM) for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction. The main questions aim to confirm that 1) the ELM can meet its intended use by validated patient reporting outcomes and 2) to confirm that the ELM device can be used safely by different users within a clinical environment as determined by review of any adverse events related to the use of the device.
Primary Outcome
Incidence of procedure-related adverse events will be assessed
Conditions Studied
Interventions
- DEVICE ELM
Study Locations (1)
California
- EYEcenter Optometric - Citrus Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2022-03-14 |
| Phase | NA |
What the finished NCT06242860 record still lists
NCT06242860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 99-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which ELM is the first listed.
NCT06242860 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06242860 about?
NCT06242860 is a clinical study titled "Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease". The goal of this clinical trial is to evaluate the Eye Lipid Mobilizer (ELM) for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction. The main questions aim to confirm that 1) the ELM can meet its intended use by validated patient reporting outcomes and 2) to con...
What is the current status of trial NCT06242860?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2022-02-08. Estimated completion is 2022-03-14.
What conditions does trial NCT06242860 study?
This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye Disease.
What interventions are being tested in trial NCT06242860?
The interventions under investigation include: ELM (DEVICE).
Who is sponsoring clinical trial NCT06242860?
This trial is sponsored by Eyedetec Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06242860 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meibomian Gland Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06242860's enrollment target sits among peer trials
31 8th of 8 higher than 1 of 8 other Meibomian Gland Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meibomian Gland Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Meibomian Gland Dysfunction Management
ACTIVE NOT RECRUITING · NA
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
COMPLETED · NA
-
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
COMPLETED · NA
-
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
COMPLETED · NA
-
Tear Film Innovations iLux Safety Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI